Proactive Investors
03 Aug 2026, 06:34 UTC · 1h ago
Genflow wins fast-track US examination for foundational longevity patent
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
03 Aug 2026, 06:34 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The US Patent and Trademark Office granted accelerated 'Track One' examination for Genflow Biosciences' foundational patent application covering its centenarian-derived SIRT6 gene variant. — Accelerated examination reduces the time to potential patent grant, which is a critical value-driver for early-stage biotech companies.
+0.40Genflow's European patent application for the SIRT6 variant has reached the final stage before the European Patent Office and is awaiting the communication that typically precedes a grant. — A pending grant in a major market like Europe expands the company's potential intellectual property moat and future commercial reach.
+0.30The US Patent Office published a second application owned by Genflow covering the use of the SIRT6 variant in treating non-alcoholic fatty liver disease (NASH). — Expanding the application to a high-demand therapeutic area like fatty liver disease increases the total addressable market for the technology.
+0.20Continue reading
6 related stories
Search tags
Which stocks this story touches
The company received accelerated examination for its foundational patent application and is progressing with other international patent filings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
